GlassScriptPhysician profile
Tiffany Wt Liu
NPI 1558705012
$10,182.30
in general payments reported to CMS, 2019-2025
40 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,114 · 2020: $632 · 2021: $712 · 2022: $406 · 2023: $2,155 · 2024: $495 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,975 · Food and Beverage: $939 · Education: $205 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,975.00 |
| Food and Beverage | $938.51 |
| Education | $204.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,902.25 | 2019-2020 | |
| Emd Serono, INC. | $2,794.01 | 2019-2024 | Mavenclad |
| Abbvie INC. | $627.80 | 2021-2025 | |
| Ucb, INC. | $569.06 | 2019-2025 | Zilbrysq, Nayzilam |
| Alexion Pharmaceuticals, INC. | $535.01 | 2019-2025 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $321.90 | 2019-2021 | |
| Amgen INC. | $291.47 | 2019-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $274.56 | 2019-2021 | |
| Lilly USA, LLC | $185.07 | 2019-2020 | |
| Sk Life Science, INC. | $169.05 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $161.72 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $160.04 | 2019-2022 | |
| Genzyme Corporation | $141.09 | 2019 | |
| Eisai INC. | $136.13 | 2019-2020 | |
| Horizon Therapeutics Plc | $108.54 | 2021-2023 | Uplizna |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $79.90 | 2019-2021 | |
| Neurelis, INC. | $67.17 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $58.73 | 2019 | |
| Amneal Pharmaceuticals LLC | $56.48 | 2019 | |
| Lundbeck LLC | $50.22 | 2019-2025 | Vyepti |
| Medtronic USA, INC. | $49.88 | 2019 | |
| Adamas Pharmaceuticals, INC. | $49.08 | 2019 | |
| Zyla Life Sciences, INC. | $37.54 | 2019 | |
| Genentech USA, INC. | $34.55 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $33.80 | 2019 | |
| Kyowa Kirin, INC. | $29.07 | 2021 | |
| Upsher-Smith Laboratories LLC | $29.02 | 2019 | |
| Supernus Pharmaceuticals, INC. | $28.20 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.86 | 2024 | Crysvita |
| Csl Behring | $23.51 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.98 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.23 | 2021 | |
| Medtronic Vascular, INC. | $16.67 | 2019 | |
| Acorda Therapeutics, INC | $16.06 | 2019 | |
| Assertio Therapeutics, INC. | $14.92 | 2019 | |
| Celgene Corporation | $14.56 | 2023 | |
| Mdd US Operations, LLC | $14.53 | 2021 | |
| Biogen, INC. | $14.30 | 2019 | |
| Grifols USA, LLC | $14.09 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.